MA
MCID: MGR028
MIFTS: 64

Migraine with or Without Aura 1 (MA)

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Migraine with or Without Aura 1

MalaCards integrated aliases for Migraine with or Without Aura 1:

Name: Migraine with or Without Aura 1 57
Migraine 57 12 73 43 53 29 54 6 42 15 62 39 32
Migraine Disorder 12 43 17
Migraine with or Without Aura, Susceptibility to, 1 57 13
Migraine Disorders 44 70
Migraine Variant 12 70
Migraines 43 15
Migraine with or Without Aura 12
Headache Including Migraine 54
Migraine, Susceptibility to 6
Headache Migrainous 43
Disorder, Migraine 43
Headache Migraine 43
Migraine Headache 43
Migraine Syndrome 43
Classic Migraine 43
Common Migraine 43
Mgau; Ma 57
Mgr1 57
Mgau 57
Ma 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant

Miscellaneous:
headache duration 4-72 hours
aggravated by physical activity
genetic heterogeneity, see, e.g., mgr2 , mgr3 , mgr4 , mgr5 , mgr6


HPO:

31
migraine with or without aura 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:6364
OMIM® 57 157300
OMIM Phenotypic Series 57 PS157300
ICD9CM 34 346
MeSH 44 D008881
NCIt 50 C89715
SNOMED-CT 67 155046006 193036004
MedGen 41 C3887485
UMLS 70 C0042331 C0149931

Summaries for Migraine with or Without Aura 1

MedlinePlus : 42 What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often) Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats Who is at risk for migraines? About 12 percent of Americans get migraines. They can affect anyone, but you are more likely to have them if you Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy. What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine. Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day. Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will Take your medical history Ask about your symptoms Do a physical and neurological exam An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Migraine with or Without Aura 1, also known as migraine, is related to familial hemiplegic migraine and migraine without aura, and has symptoms including seizures, tremor and back pain. An important gene associated with Migraine with or Without Aura 1 is NOTCH3 (Notch Receptor 3). The drugs Curcumin and Mineral oil have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and endothelial, and related phenotypes are photophobia and vomiting

Disease Ontology : 12 A brain disease that is characterized by moderate to severe headaches, nausea, extreme sensitivity to light and sound and intense unilaterial throbbing or pulsing.

MedlinePlus Genetics : 43 A migraine is a type of headache that typically causes intense, throbbing pain usually in one area of the head. People can experience migraines once a year to multiple times a week. A person is considered to have chronic migraines if they experience 15 or more headache days a month with eight of those days involving migraine headaches. Migraines typically first start during a person's teens to early twenties, but they can begin anytime from early childhood to late-adulthood.A migraine usually has three stages: the period leading up to the headache (known as the premonitory or prodromal phase), the migraine itself (the headache phase), and the period following the headache (known as the postdromal phase).The premonitory phase can start from several hours up to several days before the headache appears. In this phase, affected individuals can experience extreme tiredness (fatigue), concentration problems, and muscle stiffness in the neck. A wide variety of additional signs and symptoms can occur including excessive yawning, food cravings, irritability, depression, sensitivity to light, and nausea. About one-third of people with migraine experience a temporary pattern of neurological symptoms called an aura. An aura typically develops gradually over a few minutes and lasts between 5 and 60 minutes. Auras commonly include temporary visual changes such as blind spots (scotomas), flashing lights, and zig-zagging lines of color. Additional features of aura can include numbness, difficulty with speech and language, episodes of extreme dizziness (vertigo), and double vision. During an aura, affected individuals might experience abnormal sensations including tingling or numbness, usually of the hands or mouth. An aura usually starts within one hour of the start of a migraine. In some cases, an aura can occur without a subsequent migraine.In the headache phase, the pain may last from a few hours to a few days. Affected individuals tend to experience nausea, vomiting, dizziness, and sensitivity to light and sound in addition to headache. Some have changes in their vision or sensitivity to odors and touch.The postdromal phase usually lasts a few hours but can linger for more than a day. In this phase, the headache pain is gone but individuals can experience fatigue, drowsiness, decreased energy, concentration problems, irritability, nausea, or sensitivity to light. Affected individuals may also have brief episodes of head pain when moving their head.People with migraine, particularly women who have migraine with aura, have an increased risk of a type of stroke that is caused by a lack of blood flow to the brain (ischemic stroke), but this is a rare occurrence.There are many migraine disorders that usually include additional signs and symptoms. For example, familial hemiplegic migraine and sporadic hemiplegic migraine are characterized by migraine with associated temporary weakness that affects one side of the body (hemiparesis). Additionally, cyclic vomiting syndrome is a migraine disorder usually found in children that causes episodes of nausea and vomiting in addition to headaches.

OMIM® : 57 Migraine is the most common type of chronic, episodic headache, as summarized by Featherstone (1985). One locus for migraine with or without aura (MGR1) has been identified on chromosome 4q24. Other loci for migraine have been identified on 6p21.1-p12.2 (MGR3; 607498), 14q21.2-q22.3 (MGR4; 607501), 19p13 (MGR5; 607508), 1q31 (MGR6; 607516), 15q11-q13 (MGR7; 609179), 5q21 (with or without aura, MGR8, 609570; with aura, MGR9, 609670), 17p13 (MGR10; 610208), 18q12 (MGR11; 610209), 10q22-q23 (MGR12; 611706), and the X chromosome (MGR2; 300125). Mutation in the KCNK18 gene (613655) on chromosome 10q25 causes migraine with aura (MGR13; 613656). A subtype of autosomal dominant migraine with aura (MA), familial hemiplegic migraine (FHM; see 141500), is caused by mutation in the CACNA1A gene (601011) on chromosome 19p13 (FHM1; 141500), by mutation in the ATP1A2 gene (182340) on chromosome 1q21 (FHM2; 602481), or by mutation in the SCN1A gene (182389) on chromosome 2q24 (FHM3; 609634). Another locus for FHM has been mapped to chromosome 1q31 (FHM4; see 607516). There is evidence that a polymorphism in the estrogen receptor gene (ESR1; 133430.0005) and a polymorphism in the TNF gene (191160.0004) may confer susceptibility to migraine. A polymorphism in the endothelin receptor type A gene (EDNRA; 131243.0001) may confer resistance to migraine. (157300) (Updated 05-Apr-2021)

NINDS : 53 The pain of a migraine headache is often described as an intense pulsing or throbbing pain in one area of the head. However, it is much more; the International Headache Society diagnoses a migraine by its pain and number of attacks (at least 5, lasting 4-72 hours if untreated), and additional symptoms including nausea and/or vomiting, or sensitivity to both light and sound. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide. Roughly one-third of affected individuals can predict the onset of a migraine because it is preceded by an "aura," visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, anxiety, hormonal changes, bright or flashing lights, lack of food or sleep, and dietary substances.  Migraine in some women may relate to changes in hormones and hormonal levels during their menstrual cycle.  For many years, scientists believed that migraines were linked to the dilation and constriction of blood vessels in the head. Investigators now believe that migraine has a genetic cause.

PubMed Health : 62 About migraine: Migraine is not the same as the usual kind of headaches that most people have every now and then. A migraine attack starts suddenly with severe pain on only one side of your head. The pain is much worse than a normal headache and usually accompanied by other symptoms as well. But these headaches are only considered to be migraines if the typical symptoms have occurred at least five times. Migraines can greatly affect everyday life. Some people only get them occasionally, while others are knocked out by migraines on several days every month. Different types of medicine can help you cope with migraines.

Wikipedia : 73 Migraine (UK: /ˈmiːɡreɪn/, US: /ˈmaɪ-/) is a primary headache disorder characterized by recurrent... more...

Related Diseases for Migraine with or Without Aura 1

Diseases in the Migraine Without Aura family:

Migraine with or Without Aura 1 Migraine with or Without Aura 2
Migraine with or Without Aura 3 Migraine Without Aura 4
Migraine with or Without Aura 5 Migraine with or Without Aura 6
Migraine with or Without Aura 8 Migraine with or Without Aura 10
Migraine with or Without Aura 11 Migraine with or Without Aura 12
Migraine with or Without Aura 13

Diseases related to Migraine with or Without Aura 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1033)
# Related Disease Score Top Affiliating Genes
1 familial hemiplegic migraine 33.8 NOTCH3 MGR6 MGR5 CALCA CACNA1A
2 migraine without aura 33.5 TNF NOTCH3 EDNRA CACNA1A
3 headache 33.4 NOTCH3 EDNRA CLCN1 CALCA CACNA1A BRCA2
4 migraine with aura 32.8 NOTCH3 MGR5 MGR1 ESR1 EDNRA CALCA
5 cluster headache 32.5 CALCA CACNA1A
6 patent foramen ovale 31.9 TAB2 NOTCH3 EDNRA
7 raynaud disease 30.5 EDNRA CALCA
8 migraine, familial hemiplegic, 1 11.6
9 migraine, familial hemiplegic, 3 11.6
10 migraine, familial hemiplegic, 2 11.6
11 sporadic hemiplegic migraine 11.6
12 migraine with or without aura 13 11.6
13 migraine with brainstem aura 11.5
14 cyclic vomiting syndrome 11.4
15 familiar or sporadic hemiplegic migraine 11.3
16 retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome 11.3
17 epilepsy, familial temporal lobe, 4 11.3
18 migraine with or without aura 8 11.2
19 migraine with or without aura 2 11.2
20 migraine with or without aura 12 11.2
21 migraine with aura 7 11.2
22 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.2
23 migraine with or without aura 6 11.1
24 vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations 11.1
25 migraine without aura 4 11.1
26 migraine with or without aura 10 11.1
27 migraine with or without aura 3 11.1
28 migraine with aura 9 11.1
29 episodic ataxia 11.0
30 familial or sporadic hemiplegic migraine 11.0
31 migraine with or without aura 11 11.0
32 hemicrania continua 11.0
33 sturge-weber syndrome 11.0
34 convulsions, familial infantile, with paroxysmal choreoathetosis 11.0
35 trochleitis 11.0
36 alternating hemiplegia of childhood 1 11.0
37 carotidynia 11.0
38 ifap syndrome 2 10.9
39 migraine with or without aura 5 10.9
40 dystonia 9 10.9
41 alpha-methylacyl-coa racemase deficiency 10.9
42 peroxisome biogenesis disorder 14b 10.9
43 idiopathic hemiconvulsion-hemiplegia syndrome 10.9
44 episodic ataxia, type 2 10.9
45 orthostatic intolerance 10.9
46 celiac disease 1 10.9
47 new daily-persistent headache 10.9
48 antiphospholipid syndrome 10.9
49 retinal vasculopathy with cerebral leukodystrophy with systemic manifestations 10.9
50 phosphoglycerate kinase 1 deficiency 10.8

Comorbidity relations with Migraine with or Without Aura 1 via Phenotypic Disease Network (PDN):


Anxiety Esophagitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with or Without Aura 1:



Diseases related to Migraine with or Without Aura 1

Symptoms & Phenotypes for Migraine with or Without Aura 1

Human phenotypes related to Migraine with or Without Aura 1:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 photophobia 31 HP:0000613
2 vomiting 31 HP:0002013
3 phonophobia 31 HP:0002183
4 nausea 31 HP:0002018
5 migraine with aura 31 HP:0002077
6 migraine without aura 31 HP:0002083

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Neurologic Central Nervous System:
photophobia
phonophobia
migraine with aura
migraine without aura
headache is unilateral
more
Abdomen Gastrointestinal:
vomiting
nausea

Clinical features from OMIM®:

157300 (Updated 05-Apr-2021)

UMLS symptoms related to Migraine with or Without Aura 1:


seizures; tremor; back pain; headache; syncope; hemiplegia; pain; recurrent paroxysmal headache; nausea; chronic pain; sciatica; vertigo/dizziness; sleeplessness; scotoma, scintillating; hemicrania

MGI Mouse Phenotypes related to Migraine with or Without Aura 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.17 CACNA1A CAPN3 CLCN1 EDNRA ESR1 NOTCH3

Drugs & Therapeutics for Migraine with or Without Aura 1

PubMed Health treatment related to Migraine with or Without Aura 1: 62

A lot of people who have migraines know from experience what helps them. This often involves lying down in a quiet and dark room and putting cool wet towels or cooling pads on the side of their head that hurts. Most people take medicine to get through attacks that are especially painful. Medications used for migraine attacks include, in particular, acetaminophen (paracetamol), non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid (the drug in medicines like Aspirin ), diclofenac or ibuprofen , as well as special migraine medications like triptans. Acetaminophen (paracetamol), acetylsalicylic acid and ibuprofen are available without a prescription, as are two of the triptan drugs. But before using medication yourself it’s a good idea to see a doctor to find out if the headaches are actually migraines . Using painkillers and migraine medication too often can itself make the headaches worse. For this reason, people are advised not to take painkillers and migraine medications on more than ten days per month.

Drugs for Migraine with or Without Aura 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 458)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
2
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
3
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
4
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
5
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
6
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
7
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
8
Eletriptan Approved, Investigational Phase 4 143322-58-1 77993
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
tannic acid Approved Phase 4 1401-55-4
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
14
Ticagrelor Approved Phase 4 274693-27-5 9871419
15
Norepinephrine Approved Phase 4 51-41-2 439260
16
Ethanol Approved Phase 4 64-17-5 702
17
Ephedrine Approved Phase 4 299-42-3 9294
18
Pseudoephedrine Approved Phase 4 90-82-4 7028
19
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
20
Nadolol Approved Phase 4 42200-33-9 39147
21
Dinoprostone Approved Phase 4 363-24-6 5280360
22
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
23
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
24
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
25
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
26
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
27
Verapamil Approved Phase 4 52-53-9 2520
28
Polyestradiol phosphate Approved Phase 4 28014-46-2
29
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
30
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
31
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
32
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
33
Metronidazole Approved Phase 4 443-48-1 4173
34
Ferrous fumarate Approved Phase 4 141-01-5
35
Norethindrone Approved Phase 4 68-22-4 6230
36
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
37
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
38
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
39
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
40
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
41
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
42
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
43
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
44
Amitriptyline Approved Phase 4 50-48-6 2160
45
Propranolol Approved, Investigational Phase 4 525-66-6 4946
46
Donepezil Approved Phase 4 120014-06-4 3152
47
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
48
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
49
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
50
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606

Interventional clinical trials:

(show top 50) (show all 1052)
# Name Status NCT ID Phase Drugs
1 Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. Unknown status NCT01251263 Phase 4 Estradiol or Placebo;Estradiol or Placebo
2 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
3 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
4 Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine. A Randomized, Double-blind Trial. Unknown status NCT03698409 Phase 4
5 Nutritional Based Protocol to Balance Serotonin for the Prevention or Reduced Frequency/Duration/Intensity of Migraines Unknown status NCT00363506 Phase 4
6 IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine Unknown status NCT02664116 Phase 4 Diclofenac postassium powder for oral solution and placebo injection;Ketorolac intramuscular injection and placebo oral solution
7 Transcutaneous Suboccipital Neurostimulation for the Treatment of Chronic Migraine Unknown status NCT02307071 Phase 4
8 Double-Blind, Placebo Controlled Trial of Greater Occipital Nerve Block for the Treatment of Migraine Attacks Unknown status NCT03159000 Phase 4 Saline
9 A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack Unknown status NCT01230411 Phase 4 Ibuprofen
10 Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
11 A Prospective Trial to Evaluate the Effectiveness of Clopidogrel to Relieve Migraine With Right-to-left Shunt Unknown status NCT02938182 Phase 4 clopidogrel
12 Novel Concepts for OnabotulinumtoxinA (Botox) Mechanisms of Action: Role in Altering the Molecular Environment in Which Pain Fibers Exist Unknown status NCT03381261 Phase 4 Botulinum toxin type A
13 Ketamine v. Ketorolac for Management of Generalized Tension Type Headache Unknown status NCT03221569 Phase 4 Intravenous ketamine;Ketorolac;Normal saline;Normal saline
14 Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults Completed NCT00792636 Phase 4 sumatriptan and naproxen sodium combination tablet;sumatriptan tablet;naproxen sodium tablet
15 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
16 Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment)Of Menstrual Migraine Completed NCT00904098 Phase 4 Frovatriptan;Usual Care
17 A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms. Completed NCT00753311 Phase 4 rizatriptan or placebo
18 An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine Completed NCT01578941 Phase 4
19 Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial Completed NCT01476930 Phase 4 conventional migraine drug treatment
20 A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Acute Treatment of Migraine Headache Pain Completed NCT00297375 Phase 4 tramadol HCl/acetaminophen
21 A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans Completed NCT01016834 Phase 4 Sumatriptan
22 Ticagrelor Therapy for RefrACTORy Migraine Study Pilot (TRACTOR) Completed NCT02518464 Phase 4 Ticagrelor 90 mg twice per day
23 IV Valproate for Acute Migraine. A Randomized Comparison Versus IV Metoclopramide and IV Ketorolac Completed NCT01267864 Phase 4 Metoclopramide;Ketorolac;Valproate
24 Head-to-head Study of Erenumab Against topiRamate-a Double-blind, Double Dummy Migraine Study to Assess Tolerability and Efficacy in a patiEnt -Centered Setting Completed NCT03828539 Phase 4 Topiramate
25 Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial. Completed NCT01825941 Phase 4 metoclopramide;diphenhydramine;placebo
26 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
27 A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated. Completed NCT00637286 Phase 4 Zolmitriptan
28 A Randomized Clinical Trial to Compare Naproxen and Sumatriptan for Headache Patients Discharged From the Emergency Department (ED) Completed NCT00449787 Phase 4 Sumatriptan 100 mg;Naproxen
29 Evaluation of Histamine, CGRP and VIP as Biological Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers in Response to "Sinus" Symptoms Completed NCT00208065 Phase 4 almotriptan or pseudoephedrine
30 Treatment of Insomnia in Migraineurs With Eszopiclone (Lunesta™) and Its Effect on Sleep Time, Headache Frequency, and Daytime Functioning: a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study Completed NCT00812214 Phase 4 eszopiclone;placebo
31 Physiological and Behavioral Effects of Osteopathic Manipulative Treatment on Patients With Chronic Headache: A Randomized Clinical Trial Completed NCT01332864 Phase 4
32 Drug and Non-Drug Treatment of Severe Migraine Completed NCT00910689 Phase 4 Propranolol or nadolol;Placebo control;Optimal Acute Therapy
33 A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS Completed NCT00634985 Phase 4 eletriptan
34 A Random Controlled Trial a Comprehensive Migraine Intervention at the Time of Discharge From the Emergency Department After Treatment for Acute Migraine Completed NCT01071317 Phase 4 Naproxen;Sumatriptan
35 AXERT® Early miGraine Intervention Study (AEGIS): Efficacy and Safety of Almotriptan Malate (AXERT®) Versus Placebo for the Acute Treatment of Migraine Headache Completed NCT00210509 Phase 4 almotriptan malate
36 Open-label, 6 Month Crossover Study Evaluating Migraine Patient Satisfaction Comparing Treximet to 2 Aleve and 100mg Imitrex Taken Concomitantly Completed NCT01450995 Phase 4 Treximet;Imitrex and two Aleve
37 The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Completed NCT00719134 Phase 4 Maxalt;placebo pill;placebo pills
38 A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents Completed NCT01211145 Phase 4 Placebo;Zolmitriptan;Zolmitriptan;Zolmitriptan
39 Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine Headache in Emergency Department: Randomize Controlled Trial Completed NCT03145467 Phase 4 Paracetamol;Zolmitriptan
40 Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study) Completed NCT00799045 Phase 4 Clopidogrel
41 Greater Occipital Nerve Block for Migraine Prophylaxis Completed NCT00915473 Phase 4 bupivicaine;normal saline;methylprednisolone;lidocaine
42 Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Completed NCT02098499 Phase 4 Haloperidol;Metoclopramide 10mg;Diphenhydramine
43 Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine Over 3 Years of Treatment. A Completed NCT03606356 Phase 4 Onabotulinum toxin A
44 A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of BOTOX® and Topiramate for Headache Prophylaxis in Adults With Chronic Migraine Completed NCT02191579 Phase 4 Topiramate
45 A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine Completed NCT02147561 Phase 4
46 Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Treatment Methods Individually and in Combination With Placebo in an Acute Migraine Attack in the Emergency Department, a Prospective, Double Blind, Randomized Controlled Study Completed NCT04491474 Phase 4 Lidocaine Hydrochloride;Placebo
47 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine Completed NCT01516892 Phase 4
48 Effect of Topiramate on Cerebrovascular Response to Photic Stimulation in Migraineurs Completed NCT02424318 Phase 4 Topiramate
49 Assessment and Prevention of Menstrual Migraine: Phase 1-prospective Survey of Self-identified Menstrual Migraine. Phase 2-prevention of Menstrual Migraine With Relpax Completed NCT00259649 Phase 4 eletriptan
50 Ictal and Interictal Inflammatory Markers in Migraine Completed NCT01138150 Phase 4 Treximet;Placebo

Search NIH Clinical Center for Migraine with or Without Aura 1

Cochrane evidence based reviews: migraine disorders

Genetic Tests for Migraine with or Without Aura 1

Genetic tests related to Migraine with or Without Aura 1:

# Genetic test Affiliating Genes
1 Migraine 29 EDNRA ESR1 TNF

Anatomical Context for Migraine with or Without Aura 1

MalaCards organs/tissues related to Migraine with or Without Aura 1:

40
Brain, Cortex, Endothelial, Heart, Eye, Pituitary, Trigeminal Ganglion

Publications for Migraine with or Without Aura 1

Articles related to Migraine with or Without Aura 1:

(show top 50) (show all 30050)
# Title Authors PMID Year
1
MTHFR T677 homozygosis influences the presence of aura in migraineurs. 57 61 54
15154859 2004
2
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. 54 57 61
15014183 2004
3
CGRP may play a causative role in migraine. 54 61 57
11993614 2002
4
The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. 57 54 61
11121176 2000
5
Genome-wide meta-analysis identifies new susceptibility loci for migraine. 61 57
23793025 2013
6
Spreading depression triggers headache by activating neuronal Panx1 channels. 57 61
23449592 2013
7
Shared genetic factors in migraine and depression: evidence from a genetic isolate. 57 61
20071666 2010
8
Trait components provide tools to dissect the genetic susceptibility of migraine. 61 57
16773568 2006
9
Migraine and MTHFR C677T genotype in a population-based sample. 57 61
16365871 2006
10
Familial risk of migraine: variation by proband age at onset and headache severity. 61 57
16476932 2006
11
Migraine with aura is a risk factor for unprovoked seizures in children. 61 57
16374824 2006
12
The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. 6 61
15133719 2004
13
Localization of a gene for migraine without aura to chromosome 4q21. 57 61
14513409 2003
14
Nuclear factor-kappaB as a molecular target for migraine therapy. 57 61
11921057 2002
15
A susceptibility locus for migraine with aura, on chromosome 4q24. 57 61
11836652 2002
16
Migraine without aura: a population-based twin study. 61 57
10514097 1999
17
Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. 61 57
9989627 1999
18
Analysis of 31 families with an apparently autosomal-dominant transmission of migraine with aura in the nuclear family. 57 61
9259375 1997
19
Variation in migraine prevalence by race. 61 57
8710124 1996
20
Inheritance of migraine investigated by complex segregation analysis. 57 61
8522335 1995
21
Familial occurrence of migraine without aura and migraine with aura. 61 57
8392151 1993
22
Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. 61 57
1727198 1992
23
Familial migraine in a Mexican population. 61 57
1608495 1992
24
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. 61 57
1699472 1990
25
Segregation analysis of migraine in 128 families. 61 57
3527442 1986
26
Migraine and muscle contraction headaches: a continuum. 61 57
4019180 1985
27
Biochemical predisposition to dietary migraine: the role of phenolsulphotransferase. 61 57
6343297 1983
28
Migraine in twins. 57 61
859128 1977
29
MIGRAINE AND HEREDITY. 61 57
14322314 1965
30
Familiar occurrence of migraine headache: a study of heredity. 57 61
13196752 1954
31
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. 61 42
33781209 2021
32
Comparison of pregnenolone sulfate, pregnanolone and estradiol levels between patients with menstrually-related migraine and controls: an exploratory study. 42 61
33757421 2021
33
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. 61 42
33765912 2021
34
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
35
Antimigraine drug interactions with 5-hydroxytryptamine1A receptors. 57
2940961 1986
36
What have we learnt from triggering migraine? 54 61
20173638 2010
37
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 61 54
19936882 2010
38
Dopamine: what's new in migraine? 54 61
20164768 2010
39
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 54 61
20518725 2010
40
Migraine and obesity: epidemiology, mechanisms, and implications. 54 61
19845784 2010
41
The PACAP receptor: a novel target for migraine treatment. 61 54
20430318 2010
42
CGRP receptor antagonism and migraine. 54 61
20430315 2010
43
Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. 61 54
20188075 2010
44
Calcitonin gene-related peptide: A molecular link between obesity and migraine? 54 61
20369076 2010
45
Single nucleotide polymorphisms of the serotonin transporter gene in migraine--an association study. 54 61
19845785 2010
46
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. 54 61
20368903 2010
47
Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. 61 54
19914210 2010
48
A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis. 54 61
20080591 2010
49
Migraine models. 54 61
20336417 2010
50
Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. 54 61
19607849 2010

Variations for Migraine with or Without Aura 1

ClinVar genetic disease variations for Migraine with or Without Aura 1:

6 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PPOX NM_001122764.3(PPOX):c.1353T>G (p.Tyr451Ter) SNV Pathogenic 523355 rs148292941 GRCh37: 1:161140885-161140885
GRCh38: 1:161171095-161171095
2 CAPN3 NM_000070.3(CAPN3):c.550del (p.Thr184fs) Deletion Pathogenic 17621 rs80338800 GRCh37: 15:42680001-42680001
GRCh38: 15:42387803-42387803
3 CAPN3 NM_000070.3(CAPN3):c.1746-20C>G SNV Pathogenic 92408 rs201892814 GRCh37: 15:42695919-42695919
GRCh38: 15:42403721-42403721
4 BRCA2 NM_000059.3(BRCA2):c.4936_4939del (p.Glu1646fs) Deletion Pathogenic 37935 rs80359473 GRCh37: 13:32913425-32913428
GRCh38: 13:32339288-32339291
5 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg) SNV Pathogenic 812745 rs1555729455 GRCh37: 19:15302816-15302816
GRCh38: 19:15192005-15192005
6 CACNA1A NM_023035.3(CACNA1A):c.4186G>A (p.Val1396Met) SNV Likely pathogenic 195935 rs794727411 GRCh37: 19:13372340-13372340
GRCh38: 19:13261526-13261526
7 TAB2 NM_001292034.3(TAB2):c.1039C>T (p.Arg347Ter) SNV Likely pathogenic 373443 rs1057518422 GRCh37: 6:149700090-149700090
GRCh38: 6:149378954-149378954
8 ESR1 ESR1, 594G-A SNV risk factor 16591 GRCh37:
GRCh38:
9 NOTCH3 NM_000435.3(NOTCH3):c.1450T>G (p.Cys484Gly) SNV Likely pathogenic 523370 rs1555728965 GRCh37: 19:15299088-15299088
GRCh38: 19:15188277-15188277
10 CLCN1 NM_000083.3(CLCN1):c.950G>A (p.Arg317Gln) SNV Likely pathogenic 17542 rs80356702 GRCh37: 7:143027961-143027961
GRCh38: 7:143330868-143330868
11 DSP NM_004415.4(DSP):c.5218G>A (p.Glu1740Lys) SNV Uncertain significance 44926 rs142885240 GRCh37: 6:7581641-7581641
GRCh38: 6:7581408-7581408
12 MYH6 NM_002471.4(MYH6):c.3195G>C (p.Gln1065His) SNV Uncertain significance 14149 rs267606904 GRCh37: 14:23862177-23862177
GRCh38: 14:23392968-23392968
13 MYH6 NM_002471.3(MYH6):c.4594C>T (p.Arg1532Cys) SNV Uncertain significance 239175 rs201827489 GRCh37: 14:23856794-23856794
GRCh38: 14:23387585-23387585
14 STIM1 NM_001277961.1(STIM1):c.1534T>A (p.Ser512Thr) SNV Uncertain significance 523431 rs1554971682 GRCh37: 11:4107766-4107766
GRCh38: 11:4086536-4086536
15 SLC2A1 NM_006516.3(SLC2A1):c.1407G>C (p.Gln469His) SNV Uncertain significance 374095 rs201748668 GRCh37: 1:43392784-43392784
GRCh38: 1:42927113-42927113
16 AHNAK2 NM_138420.4(AHNAK2):c.6406_6408delinsGAC (p.Gln2136Asp) Indel Uncertain significance 983126 GRCh37: 14:105415380-105415382
GRCh38: 14:104949043-104949045
17 SCN5A NM_000335.5(SCN5A):c.892G>A (p.Gly298Ser) SNV Uncertain significance 9387 rs137854608 GRCh37: 3:38651267-38651267
GRCh38: 3:38609776-38609776
18 MAP2K2 NM_030662.3(MAP2K2):c.514A>G (p.Lys172Glu) SNV Uncertain significance 523536 rs1413580671 GRCh37: 19:4102388-4102388
GRCh38: 19:4102390-4102390

Copy number variations for Migraine with or Without Aura 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 39736 10 118956999 118969809 Copy number KCNK18 Migraine

Expression for Migraine with or Without Aura 1

Search GEO for disease gene expression data for Migraine with or Without Aura 1.

Pathways for Migraine with or Without Aura 1

GO Terms for Migraine with or Without Aura 1

Biological processes related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 8.96 TNF ESR1
2 positive regulation of cytosolic calcium ion concentration GO:0007204 8.92 ESR1 EDNRA CALCA CACNA1A

Sources for Migraine with or Without Aura 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG